Komori
Human Metabolome Technologies (6090) · InitiativeAchieved

Offsetting accumulated losses through reductions in capital reserves and appropriation of surplus

First written in FY2022. 1 of 2 entries say "Achieved", first in FY2023-Q1. Latest entry: FY2023-Q1.

2entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20222022: 22022
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 287 companies write about · 1 as a headwind · 286 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 289 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2023-Q1AchievedAnnual report

    「At the 19th annual shareholders’ meeting held on 22 September 2022, the company passed resolutions under Article 448, Paragraph 1 of the Companies Act concerning the reduction of capital reserve and disposition of surplus. Effective 30 September 2022, it reduced its capital reserve by ¥1,470.317 million and transferred the same amount to other capital surplus. Under Article 452 of the Companies Act, it also transferred ¥1,470.317 million of other capital surplus to retained earnings.」

    Based on the shareholders’ meeting resolution, ¥1,470.317 million of capital reserve was reduced and transferred to other capital surplus and then to retained earnings on 30 September 2022.
  2. FY2022First statedAnnual report

    「At the end of the 19th fiscal year, the company had an accumulated deficit in retained earnings. To secure flexibility and agility in its future capital and financial strategies, the company intends to carry out procedures under Article 448, Paragraph 1 of the Companies Act to reduce the amount of its capital reserve and transfer it to other capital surplus, and under Article 452 of the Companies Act to transfer the other capital surplus after the first transfer to retained earnings.」

    The company disclosed procedures to reduce its capital reserve of ¥1,470.317 million in full and transfer the amount to retained earnings through other capital surplus. The measure was approved at the shareholders’ meeting on 22 September 2022, with 30 September 2022 as the effective date.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.